ETHICON Introduces New Device to Treat Stress Incontinence
ATHENS, Greece, Sept. 5 (HSMN NewsFeed) -- ETHICON Women's Health & Urology will announce at the annual meeting of the International Urogynecological Association (IUGA) this week that the GYNECARE TVT SECUR* System is available for use to treat female stress urinary incontinence (SUI). This new midurethral sling device maintains the elements that made GYNECARE TVT the gold standard in SUI repair, yet offers a small, innovative design that facilitates a less invasive treatment approach and eliminates patient discomfort associated with skin exits.
GYNECARE TVT SECUR features a PROLENE* Polypropylene Mesh implant that is four times shorter in length than traditional slings. The mesh tape is introduced to the patient using a novel "attach and release" mechanism that allows for stable and controlled placement, resulting in no skin exits. Absorbable fixation tips made of Vicryl* (polyglactin 910) knitted mesh and PDS* (polydioxanone) suture yarn provide mechanical fixation until complete tissue ingrowth occurs. The device is designed for use in a 10- to 15-minute procedure that can be used with local anesthesia.
"The TVT sling changed our thinking about the treatment of SUI, and over time it has proven to be safe and effective," said Mickey Karram, M.D., FACOG, director of Urogynecology at Good Samaritan Hospital in Cincinnati, Ohio, and Professor of Obstetrics and Gynecology at the University of Cincinnati School of Medicine. "I believe this new technique builds on the clinical experience and offers a more patient-friendly approach that has the potential to reduce some of the reported complications associated with midurethral slings."
Dr. Karram, who is the lead U.S. investigator for the device, will share his early clinical experience at a symposium at IUGA on September 8.
ABOUT GYNECARE TVT
The GYNECARE TVT SECUR System uses the same unique PROLENE Mesh used in over one million patients worldwide, and has been proven safe and effective with seven years of clinical data. The mesh is inserted through the vagina and positioned underneath the urethra, creating a supportive sling. During movement or exercise, the mesh supports the urethra, allowing it to maintain its seal to prevent urine loss. The tape provides support only when needed, without any unnecessary tension on the urethra (tension-free).
The treatment is not intended for women who are or intend to become pregnant. Women on anticoagulation therapy also are not candidates.
The family of GYNECARE TVT products is marketed by ETHICON Women's Health & Urology, a division of Ethicon, Inc., a Johnson & Johnson company.
For more information and full product information visit http://www.jnjgateway.com.
* Trademark of Ethicon, Inc.
|
Public
Feeds 
